News and Comments

Pharmacyclics: When the Power of Biotechs' Pipelines Overshadows the Market’s influence on the Firms' Values.

  Thursday, February 23, 2012

Pharmacyclic’s (PCYC) story is one of a few where the power of pipeline drugs has overshadowed the stock market’s technical influence on the biotech companies’ values. In other words, in the case of Pharmacyclics, investors should be looking for something extraordinary in the firm’s pipeline, in its choices of its programs, in its plans and strategies in developing its pipeline products and its capability of executing its plans and reaching its goals. Pharmacyclics’ Bruton’s tyrosine Kinase (BTK) inhibitor PCI-32765 therapeutic is unique. In December 2011, Pharmacyclics was granted U.S. patent that testifies to the drug’s exceptionality. It is, indeed, the first irreversible inhibitor in the BTK zone.     More...

Illumina, Roche and Fairness

  Thursday, February 09, 2012

Illumina (ILMN) is occupying the center stage these days. Roche’s persistent attempts to acquire ILMN, has opened investors’ eyes on the importance of this firm’s technology in moving away from the road of stagnation to that of innovation. Innovation is the insurance that guarantees the survival and growth of the drug companies in the future that has already begun. Illumina’s technologies and marketed state-of-the-art sequencers and gene analyzers have been a major contributor to the flourishing of information about the origins of diseases at the molecular level.  This capability, which lured Roche, was overlooked by Wall Street investors who have recently caused a selloff in the stock for theorized reasons. The real value of Illumina resides in its indispensability as the cornerstone of future advancement in medical diagnosis and treatment. With all the new-targeted drugs on the market and in the firms’ pipelines, the current diagnostic and treatment statuses are still far from perfect. More...

Recent Postings



Revlimid (lenolidamide) Bristol-Myers Squibb (BMY) NEUROCRINE (NBIX) Illumina (ILMN) Endometrial Cancer Xoma (XOMA) SUNESIS PHARMACEUTICALS (SNSS) Ziofpharm (ZIOP) Onyx (ONXX) Ocular Therapeutix (OCUL) Sangamo (SGMO) TOKAI (TKAOI) JOUNCE THERAPEUTICS (JNCE) Rapamune HALOZYME (HALO) Agenus (AGEN) Intrexon (XON) Incyte (INCY) Bellicum (BLCM) Human Genome Sciences (HGSI) C4 Therapeutics Vertex (VRTX) GUARDIAN HEALTH Sanofi (SNY) Biocryst (BCRX) Velcade (bortezomib) NANTKWEST (NK) CEMPRA (CEMP) Roche (RHHBY) Trastuzumab-DM1 Cytokinetics (CYTK) Idenix (IDIX) Amgen (AMGN) OncoCyte (OCX) AstraZeneca (AZN) Regeneron (REGN) Tysabri Multiple Myeloma ACADIA (ACAD) IDERA (IDRA) Zerenex Agenus (AGEN Human Longevity (HLI) Aimmune Therapeutics (AIMT) REGULUS (RGLS) JUNO (JUNO) Jazz Pharmaceuticals (JAZZ) Alnylam (ALNY) Ridaforolimus Elan (ELN) ISIS (ISIS) SERES THERAPEUTICS (MCRB) Anacor (ANAC) Sequenom (SQNM) GlaxoSmithKline (GSK) KERYX (KERX) Roche (ROCHE) SYNTA (SNTA) Intercept (ICPT) Benlysta (belimumab) Herceptin ARGOS (ARGS) Inovio (INO) Adaptimmune (ADAP) ABBVIE (ABBV) LEXICON (LXRX) Advaxis (ADXS) Genentech ImmunoGen (IMGN) galapagos (GLPG) Valeant Pharmaceuticals International (VRX) RenenxBio (RGNX) KITE (KITE) Dendreon (DNDN) CompuGen (CGEN) Intermune (ITMN) Abbott Laboratories (ABT) Dynavax (DVAX) OSI (OSIP) Exelixis (EXEL) AGOS (ARGS) AERIE PHARMACEUTICALS INNOVIVA (INVA) Spike Therapeutics (ONCE) Vitae Pharmaceuticals (VTAE) Auspex (ASPX) VANDA (VNDA) Merck (MRK) Theravance Bio Pharma (TBPH) Galena (GALE) BIOMARIN (BMRN) Ariad (ARIA) ZALTRAP™ Prolor Biotech (PBTH) Anadys (ANDS) Ionis (IONS) Sanofi-Aventis (SAN) ADVENTRIX (ANX) Micromet (MITI) Sarepta (SRPT) PORTOLA (PTLA) Sanofi (SNA) Global Cell Therapeutics (GBT) Gilead (GILD) Mirati Therapeutics (MRTX) Array Pharmaceuticals (ARRY) MODERNA Prosensa (RNA) Telaprevir NOVOCURE (NVCR) NEKTAR (NKTR)) Biogen Idec (BIIB) CRISPR Therapeutics (CRSP) PTC Therapeutics (PTCT) Seattle Genetics (SGEN) Pluristem (PSTI) Theravance (THRX) ARCA (ABIO) Alder Biopharmaceuticals (ALDR) Editas (EDIT)